부산대학교 도서관

Background: Evidence indicates the protective role of Irisin on nervous tissue following ischemic events, by preventing the cascades of secondary damage. We conducted this scoping review to summarize what has been discovered so far on the neuroprotective effects of Irisin, with a focus on ischemic stroke. Methods: Search strategies were designed based on the keywords related to ischemic stroke and Irisin. Next, an extensive search in Medline, Embase, Scopus, and Web of Science was conducted by the end of April 2022. Two researchers independently reviewed the articles and performed the screening of the selected papers according to the inclusion criteria. Finally, the required data were extracted to a checklist designed based on the PRISMA guideline. The "meta" package was used for the meta-analysis, and heterogeneity between studies was assessed using the I2 test. Results: Pooled data analysis showed that the Irisin administration significantly improved the neurological function following cerebral ischemia / reperfusion injuries (SMD = 3.08; 95% CI: 1.10, 5.06; p<0.0001). Additionally, meta-regression demonstrated that the improvement in neurological function was directly related to the dose of administered Irisin (meta-regression coefficient = 0.03; p = 0.02). Moreover, Irisin administration significantly reduced the volume of infarcted lesions (SMD= -3.14; 95% CI: -4.23, -2.04; p<0.0001), the amount of edema in the brain (SMD= -2.30; 95% CI: -4.07, -0.53; p<0.0001), and the extend of neuronal-cell apoptosis rate (SMD= -4.67; 95% CI: -8.15, -1.19; p<0.0001). Conclusion: The present study demonstrates that the administration of Irisin in animal models of cerebral ischemia / reperfusion injuries is associated with a significant dose-dependent improvement in neurological function. Due to the limited number of articles, more research on the aim of finding the optimum Irisin dosage is in high demand. [ABSTRACT FROM AUTHOR]